Enliven Therapeutics
ELVN
38 hedge funds and large institutions have $62.5M invested in Enliven Therapeutics in 2021 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 11 increasing their positions, 8 reducing their positions, and 10 closing their positions.
70% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 10
38% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 8
23% more funds holding
Funds holding: 31 → 38 (+7)
0.89% less ownership
Funds ownership: 15.49% → 14.59% (-0.89%)
28% less capital invested
Capital invested by funds: $86.3M → $62.5M (-$23.8M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $60K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$8.66M |
| 2 |
LPC
Lion Point Capital
New York
|
+$4.33M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$4.31M |
| 4 |
LCM
Laurion Capital Management
New York
|
+$1.56M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$1.97M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.74M |
| 3 |
Russell Investments Group
London,
United Kingdom
|
-$1.53M |
| 4 |
Morgan Stanley
New York
|
-$719K |
| 5 |
TEE
Tibra Equities Europe
London,
United Kingdom
|
-$296K |
ELVN Hedge Fund Activity: Q3 2021 in Review
38 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Enliven Therapeutics (ELVN) for Q3 2021, worth a combined $62.5M — down 28% from $86.3M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new ELVN positions and 10 closed out — a net gain of 7 holders — while 11 added to existing stakes and 8 trimmed.
The largest buyer was OrbiMed, adding an estimated $8.66M. The largest seller was RA Capital Management, exiting entirely with an estimated $1.97M sold.
- 38 institutional investors held Enliven Therapeutics (ELVN) as of Q3 2021, up from 31 in Q2 2021.
- Funds reported $62.5M of Enliven Therapeutics stock for Q3 2021, down 28% quarter-over-quarter.
- 17 funds opened new Enliven Therapeutics positions in Q3 2021 and 10 closed out, a net change of +7 holders.
- The largest Enliven Therapeutics buyer in Q3 2021 was OrbiMed, an estimated $8.66M added.
- The largest Enliven Therapeutics seller in Q3 2021 was RA Capital Management, an estimated $1.97M sold.
Based on aggregated 13F filings for Q3 2021.